Skip to content

Abstract 16799: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Prior Myocardial Infarction and Overweight or Obesity: A Propensity-Matched Analysis

Nov 2026 · Circulation · 0 citations

TL;DR

In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality.

Abstract

Introduction: Patients with prior myocardial infarction (MI) and overweight or obesity face high residual risk of recurrent cardiovascular events and heart failure. GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) are widely used in this group, yet their comparative cardiovascular effects are poorly defined. Hypothesis: GLP-1 RA use is associated with lower risk of major adverse cardiovascular events (MACE) and new-onset heart failure than SGLT2i in post-MI patients with overweight or obesity. Methods: Using the TriNetX Global Collaborative Network, we identified adults aged 18 to 85 with prior MI and overweight or obesity who started GLP-1 RA or SGLT2i on or after January 2012, excluding users of the other drug class (Figure 1). Propensity score matching on 50 covariates (demographics, diagnoses, medications, and laboratory values) produced 18,803 well-matched pairs (all standardized differences below 0.02). Co-primary outcomes were MACE (composite of acute MI, ischemic stroke, cardiac arrest, and cardiac arrhythmia) and new-onset heart failure. Secondary outcomes were recurrent MI, ischemic stroke, pulmonary hypertension, atrial fibrillation, and all-cause mortality. Hazard ratios (HR) were estimated using Cox models. Results: Matched cohorts were balanced (mean age 63 years, 61% male, 71% diabetes; median follow-up about 1.5 years). GLP-1 RA was associated with lower risk of MACE (HR 0.75, 95% CI 0.66 to 0.84; 10.6% vs 13.5%) and new-onset heart failure (HR 0.58, 95% CI 0.53 to 0.63; 8.9% vs 15.4%; both p<0.001) (Figure 2). Benefit extended to recurrent MI (HR 0.75), ischemic stroke (HR 0.85), and pulmonary hypertension (HR 0.78; all p<0.05). All-cause mortality (HR 0.95, 95% CI 0.89 to 1.02) and atrial fibrillation (HR 0.91) did not differ significantly, and a negative-control outcome (hip fracture, HR 1.02) confirmed no systematic bias. Conclusion: In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality. These findings support a preferential cardioprotective role for GLP-1 RA and warrant prospective confirmation.

View source

Similar papers

Nov 2026

Abstract 14486: Comparative Cardiovascular and Mortality Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study

GLP-1 RA therapy was associated with significantly lower risks of major adverse cardiovascular outcomes and all-cause mortality compared with SGLT2 inhibitors, suggesting a potential advantage of GLP-1 RA therapy for long-term cardiovascular risk reduction in patients with T2DM.

Sajjad Ahmed Khan, Anurag Marasini · 0 citations
Nov 2026

Abstract 8806: Comparative Efficacy of GLP-1 Receptor Agonists versus SGLT-2 Inhibitors for Limb Outcomes in Patients with Peripheral Artery Disease: A Multicenter Propensity Score-Matched Real-World Study

Background: Patients with peripheral artery disease (PAD) face high risks of limb loss, revascularization, and cardiovascular events. While both GLP-1 receptor agonists (GLP-1 RAs) and SGLT-2 inhibitors (SGLT-2is) improve cardiovascular outcomes in type 2 diabetes, their comparative effectiveness on limb-specific ou...

Ibrahim Khalil, Pallab Sarker, M. Hossain et al. · 0 citations
Nov 2026

Abstract 14489: GLP-1 Receptor Agonists vs. SGLT2 Inhibitors and Risk of Atrial Fibrillation in Patients with Obstructive Sleep Apnea and Obesity: A Propensity-Matched Analysis

Introduction: Obstructive sleep apnea (OSA) and obesity are established risk factors for atrial fibrillation (AF) through shared mechanisms including chronic intermittent hypoxia, sympathetic activation, and atrial remodeling. GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) are increasingly used in...

Zaid Al-Kofahi, H. Alhammouri, F. Qtaishat et al. · 0 citations
Nov 2026

Abstract 9771: Cardiovascular and Mortality Outcomes Associated with GLP-1 Receptor Agonists Among Adults with Prediabetes: A Propensity-Matched Real-World Cohort Study

Introduction: Prediabetes is a growing global health burden associated with elevated cardiovascular risk well before overt diabetes. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) confer cardiovascular benefit in type 2 diabetes and obesity, real-world data in overweight or obese adults with prediabet...

F. Qtaishat, H. Alhammouri, J. Yasin et al. · 0 citations
Nov 2026

Abstract 19032: GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in Patients with Atherosclerotic Cardiovascular Disease and Obesity

Background: Statins reduce cardiovascular events in atherosclerotic cardiovascular disease (ASCVD), yet residual risk remains high in patients with obesity. Whether adding a GLP-1 receptor agonist (GLP-1 RA) to statin therapy further reduces mortality, myocardial infarction (MI), and ischemic stroke in this populati...

Sunanda Tah, E. Okorigba, M. Cheshire · 0 citations
Open access Nov 2026

Clinical Outcomes Following GLP-1 Receptor Agonist Initiation With Versus Without Background SGLT2 Inhibitor Therapy in Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes: A Propensity-Matched Real-World Analysis

SGLT2 inhibitors (SGLT2i) improve heart failure outcomes, and GLP-1 receptor agonists (GLP-1 RA) confer cardiometabolic benefit. However, outcomes after GLP-1 RA initiation according to background SGLT2i use remain uncertain. Using TriNetX, we compared GLP-1 RA initiation in patients with HFpEF and type 2 di...

Vikash Jaiswal, M. Banach, Asmita Gera et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.